Scholarlink

<p>Metabolic dysfunction-associated fatty liver disease (MAFLD) is a prevalent metabolic disorder that can progress from simple steatosis to chronic inflammation and fibrosis. Currently, pharmacological agents for MAFLD remain limited, and lifestyle-based management often fails to halt disease progression, underscoring the need for multitarget therapeutic strategies. Mesenchymal stem cells (MSCs) represent a promising regenerative and immunomodulatory therapy capable of reprogramming the hepatic inflammatory microenvironment, improving metabolic homeostasis, and limiting fibrogenesis. Increasing evidence indicates that MSC efficacy is largely mediated through paracrine mechanisms, with MSC-derived small extracellular vesicles (MSC-EVs) acting as key effectors by delivering functional cargos, including microRNAs (miRNAs) and proteins. MSC-EVs attenuate inflammation <i>via</i> inflammasome inhibition and macrophage polarization, restore insulin sensitivity and lipid handling through AMP-activated protein kinase (AMPK)-associated metabolic signaling, and also limit fibrogenesis by suppressing hepatic stellate cell (HSC) activation as part of their integrated multitarget actions. This review integrates current insights into MAFLD pathogenesis and the therapeutic mechanisms of MSCs and MSC-EVs, and highlights translational priorities for their clinical development.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mesenchymal stem cells and extracellular vesicles for MAFLD: from biological mechanisms to translational prospects

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月29日

查看全文
  • Zhennan Huang,
  • Yiheng Pan,
  • Naishun Liao,
  • Fan Pan

摘要

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a prevalent metabolic disorder that can progress from simple steatosis to chronic inflammation and fibrosis. Currently, pharmacological agents for MAFLD remain limited, and lifestyle-based management often fails to halt disease progression, underscoring the need for multitarget therapeutic strategies. Mesenchymal stem cells (MSCs) represent a promising regenerative and immunomodulatory therapy capable of reprogramming the hepatic inflammatory microenvironment, improving metabolic homeostasis, and limiting fibrogenesis. Increasing evidence indicates that MSC efficacy is largely mediated through paracrine mechanisms, with MSC-derived small extracellular vesicles (MSC-EVs) acting as key effectors by delivering functional cargos, including microRNAs (miRNAs) and proteins. MSC-EVs attenuate inflammation via inflammasome inhibition and macrophage polarization, restore insulin sensitivity and lipid handling through AMP-activated protein kinase (AMPK)-associated metabolic signaling, and also limit fibrogenesis by suppressing hepatic stellate cell (HSC) activation as part of their integrated multitarget actions. This review integrates current insights into MAFLD pathogenesis and the therapeutic mechanisms of MSCs and MSC-EVs, and highlights translational priorities for their clinical development.